Elevated LDH Serum Levels and FDG-PET in Metastatic Melanoma Patients

University Medical Center Groningen (UMCG)

Status: Completed

Conditions: Melanoma

Study type: Observational

Funder types: Other

Identifiers

NCT02949154

201600693

Details and patient eligibility

About

A retrospective study investigating the relationship between FDG-PET uptake and LDH levels.

Full description

Patient characteristics, tumour characteristics including the BRAF mutation status and baseline serum S100B and LDH levels of each patient will be retrospectively determined from the electronical patient file. In each patient, tumour burden and 18F-FDG uptake of the tumour lesions will be measured using multiple standard quantification parameters of the baseline 18F-FDG-PET scan. Tumour burden will also be measured on the baseline contrast enhanced CT scan. The correlation of each FDG-PET parameter with baseline LDH and S100B levels, respectively, will be analyzed using univariate and multivariate regression analysis.

Enrollment: 65 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients >18 years with histologically proven metastatic melanoma (American Joint Committee on Cancer [AJCC] stage IV melanoma) treated in the UMCG between May 2014 and December 2015.

Exclusion criteria

• participation in interventional studies
• missing baseline 18F-FDG PET scan and/or baseline contrast enhanced CT scan
• missing baseline serum LDH level
• missing BRAF mutation status, concurrent malignancies or a history of previous malignancies.

Trial design

65 participants in 1 patient group

Metastatic melanoma patients

Description:

All patients \>18 years with histologically proven metastatic melanoma (American Joint Committee on Cancer \[AJCC\] stage IV melanoma) treated in the UMCG between May 2014 and December 2015.